JP2001318095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001318095A5 JP2001318095A5 JP2000135043A JP2000135043A JP2001318095A5 JP 2001318095 A5 JP2001318095 A5 JP 2001318095A5 JP 2000135043 A JP2000135043 A JP 2000135043A JP 2000135043 A JP2000135043 A JP 2000135043A JP 2001318095 A5 JP2001318095 A5 JP 2001318095A5
- Authority
- JP
- Japan
- Prior art keywords
- opioid
- disease
- pruritus
- measured
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 108010093625 Opioid Peptides Proteins 0.000 description 5
- 102000001490 Opioid Peptides Human genes 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003399 opiate peptide Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001823 pruritic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000135043A JP4370683B2 (ja) | 2000-05-08 | 2000-05-08 | そう痒疾患の検査方法 |
| US09/704,319 US6984493B1 (en) | 2000-05-08 | 2000-11-02 | Method for examining the involvement of opioid peptides in prurtis |
| CA002324982A CA2324982A1 (en) | 2000-05-08 | 2000-11-02 | Method for examining disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000135043A JP4370683B2 (ja) | 2000-05-08 | 2000-05-08 | そう痒疾患の検査方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001318095A JP2001318095A (ja) | 2001-11-16 |
| JP2001318095A5 true JP2001318095A5 (cg-RX-API-DMAC7.html) | 2007-10-18 |
| JP4370683B2 JP4370683B2 (ja) | 2009-11-25 |
Family
ID=18643206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000135043A Expired - Fee Related JP4370683B2 (ja) | 2000-05-08 | 2000-05-08 | そう痒疾患の検査方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6984493B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4370683B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2324982A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005011113D1 (de) * | 2004-03-30 | 2009-01-02 | Toray Industries | Morphinanderivate als mittel gegen juckreiz |
| KR101334401B1 (ko) | 2006-04-11 | 2013-11-29 | 한국생명공학연구원 | 아토피 피부 질환의 기전을 모니터링 할 수 있는 아토피피부 질환의 진단 또는 치료용 마커 단백질 |
| KR101257307B1 (ko) | 2006-05-22 | 2013-04-23 | 한국생명공학연구원 | 인간 혈청 프로테옴에서 발굴한 아토피 피부 질환의 기전을모니터링 할 수 있는 아토피 피부 질환의 진단 또는치료용 마커 단백질 |
| WO2011049433A1 (en) * | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
| US20140066475A1 (en) | 2012-09-04 | 2014-03-06 | Euro-Celtique S.A. | Method For Treating Pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| KR20150003059A (ko) * | 2013-06-28 | 2015-01-08 | 김종배 | 뇨 중 글리아돌핀(Gliadorphin) 농도 측정을 위한 면역분석법 |
| CA3091752A1 (en) | 2018-03-08 | 2019-09-12 | Victoria Link Ltd | Treatment of demyelinating diseases |
| CN118512451A (zh) | 2018-07-23 | 2024-08-20 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
-
2000
- 2000-05-08 JP JP2000135043A patent/JP4370683B2/ja not_active Expired - Fee Related
- 2000-11-02 US US09/704,319 patent/US6984493B1/en not_active Expired - Fee Related
- 2000-11-02 CA CA002324982A patent/CA2324982A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pinzani et al. | Liver cirrhosis | |
| Noori et al. | Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis | |
| Whicher et al. | When is serum albumin worth measuring? | |
| WO2005010213A3 (en) | Markers for detection of gastric cancer | |
| WO2000052463A1 (en) | Method of diagnosing and monitoring malignant breast carcinomas | |
| WO2004039244A3 (en) | Methods and kits for diagnosing tumorigenicity | |
| Toering et al. | Higher filtration fraction in formerly early-onset preeclamptic women without comorbidity | |
| Drayer et al. | Low and high renin essential hypertension: a comparison of clinical and biochemical characteristics | |
| Borowsky et al. | Elevation of serum angiotensin-converting enzyme level: occurrence in alcoholic liver disease | |
| Davenport et al. | Hydration status does not influence peritoneal equilibration test ultrafiltration volumes | |
| Gallardo et al. | Increased plasma levels of atrial natriuretic peptide and endocrine markers of volume depletion in patients with obstructive jaundice | |
| JP4370683B2 (ja) | そう痒疾患の検査方法 | |
| JP2004513074A5 (cg-RX-API-DMAC7.html) | ||
| Akarsu et al. | Relation between serum ubiquitin levels and KT/V in chronic hemodialysis patients | |
| Krediet et al. | The physiology and pathophysiology of peritoneal transport | |
| WO2002072752A3 (en) | Forms of prostate specific antigens and methods for their detection | |
| Mori et al. | Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non‐alcoholic fatty liver disease | |
| DK1263381T3 (da) | Dametrusseindlæg, især til gravide | |
| JP2000214163A5 (cg-RX-API-DMAC7.html) | ||
| Corvol | Tumor-dependent hypertension. | |
| CN216394117U (zh) | 一种医疗检测用尿液取样装置 | |
| CN206177965U (zh) | 一种测定早孕结果的试纸 | |
| CN205691597U (zh) | 一种可拆酶标板 | |
| Tzamaloukas et al. | Adequacy of continuous ambulatory peritoneal dialysis | |
| Degoricija et al. | Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial |